AnaptysBio Inc.
Last updated September 27, 2026
Organization details
- Legal name
- AnaptysBio Inc.
- Former names
- Anaptys Biosciences Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- June
- Ticker symbol
- ANAB
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001370053
- EIN
- 20-3828755
Board of directors
-
Daniel Faga · Director · President, CEOSince 2023
-
Dennis M. Fenton · DirectorSince 2023
-
Hollings Renton · DirectorSince 2023
-
J. Anthony Ware · DirectorSince 2023
-
James N. Topper · DirectorSince 2023
-
John A. Orwin · DirectorSince 2023
- Since 2023
-
Laura Hamill · DirectorSince 2023
- Since 2023
-
Oleg Nodelman · DirectorSince 2025
-
Owen Hughes · DirectorSince 2026
- Since 2023
-
Susannah Gray · DirectorSince 2026
Chief executives
Daniel Faga
· CEO
Dates unknown
Director election results
Annual meeting of June 17, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.9%
-
84.2%
-
93.1%
Board connections
13 of this board's directors also sit on 26 other boards.
- via Daniel Faga, Dennis M. Fenton, J. Anthony Ware, John A. Orwin, John P. Schmid, Magda Marquet and Rita Jain
- via Hollings Renton and Oleg Nodelman
- via Susannah Gray
- via Oleg Nodelman
- via Magda Marquet
- via James N. Topper
- via Rita Jain
- via John P. Schmid
- via John P. Schmid
- via Owen Hughes
- via Rita Jain
- via John P. Schmid
- via Laura Hamill
- via John P. Schmid
- via Owen Hughes
- via Magda Marquet
- via Laura Hamill
- via Susannah Gray
- via James N. Topper
- via Oleg Nodelman
- via James N. Topper
- via Rita Jain
- via Laura Hamill
- via Magda Marquet
- via John A. Orwin
- via John P. Schmid
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $9,741,886
- 42 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | John A. Orwin Director | Option exercise | +1,300 | — | — |
| Jun 15, 2026 | John P. Schmid Director | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | Hollings Renton Director | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | John A. Orwin Director | Option exercise | +6,030 | — | — |
| Mar 30, 2026 | John P. Schmid Director | Open-market sale | −12,596 | $55.71 | $701,723 |
| Mar 30, 2026 | John P. Schmid Director | Open-market sale | −7,527 | $56.70 | $426,781 |
| Mar 30, 2026 | John P. Schmid Director | Open-market sale | −522 | $57.40 | $29,963 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −510 | $56.61 | $28,871 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −2,570 | $57.91 | $148,829 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −3,662 | $58.62 | $214,666 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −490 | $59.62 | $29,214 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −550 | $60.63 | $33,347 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −1,012 | $62.15 | $62,896 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −2,592 | $63.35 | $164,203 |
| Mar 27, 2026 | Daniel Faga Director, Officer (President, CEO) | Open-market sale | −3,155 | $64.19 | $202,519 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.